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The presymptomatic phase of neurodegenerative diseases are characterised by structural brain 
changes without significant clinical features. We set out to investigate the contribution of functional 
network resilience to preserved cognition in pre-symptomatic genetic frontotemporal dementia. We 
studied 172 people from families carrying genetic abnormalities in C9orf72, MAPT or PGRN. 
Networks were extracted from functional MRI data and assessed using graph theoretical analysis. 
We found that despite loss of both brain volume and functional connections, there is maintenance of 
an efficient topological organisation of the brain’s functional network in the years leading up to the 
estimated age of frontotemporal dementia symptom onset. After this point, functional network 
efficiency declines markedly. Reduction in connectedness was most marked in highly connected 
hub regions. Measures of topological efficiency of the brain’s functional network and organisation 
predicted cognitive dysfunction in domains related to symptomatic frontotemporal dementia and 
connectivity correlated with brain volume loss in frontotemporal dementia. We propose that 
maintaining the efficient organisation of the brain’s functional network supports cognitive health 
even as atrophy and connectivity decline pre-symptomatically. 
 
Keywords: Frontotemporal dementia; Genetics; Connectivity; Functional imaging; Cognition 
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Many neurodegenerative dementias begin their neuropathology years or even decades before the 
onset of symptoms. The evidence of pre-symptomatic pathology comes from changes in structural 
brain imaging, PET ligands that bind to pathological proteins, and abnormal cerebrospinal fluid and 
blood biomarkers1–3. However, it is not clear why people with significant progressive 
neurodegeneration and brain volume loss remain free of symptoms for so long, or develop 
symptoms when they do. To address this issue we assessed functional network resilience in the 
Genetic Frontotemporal Dementia Initiative (GENFI) cohort3. 
 
Network resilience derives from the robust and efficient arrangement of connections between brain 
regions4. This arrangement is characterised by the presence of highly connected hubs5,6 in a ‘small 
world’ arrangement which minimises the topological distance (also called path length) between 
parts of the network. This path length can be used to derive measures of global or regional network 
efficiency. Networks that have an efficient small world topology are intrinsically robust to processes 
that damage the network by removing network nodes or connections7. 
 
Examining the network organisation of the brain has provided critical insights into neurocognitive 
development8, and diverse disorders of the nervous system from multiple sclerosis9,10, depression11, 
schizophrenia12 and autism13, to multiple neurodegenerative diseases including frontotemporal 
dementia (FTD)14–16, Alzheimer’s disease, Parkinson’s disease17,18, and Progressive Supranuclear 
Palsy18,19. In patients, altered network connectivity is consistently associated with the loss of 
cognitive function20,21 or reduced response to treatment22,23. In contrast, here we assess whether 
network integration provides resilience at earlier stages of the disease process, with the maintenance 
of cognitive well-being, even in the presence of established neuropathology and brain atrophy. To 
be more specific, we assess functional network resilience, which is defined as the maintenance of 
the topological properties of a functional brain network in the context of structural changes to the 
brain. 
 
We identified functional brain networks from functional MRI (fMRI) images, using the Blood 
Oxygen Level Dependent effect as an indirect measure of neural activity. The advent of task-free 
fMRI (also called “resting state” fMRI)24  has facilitated the analysis of brain function in severely 
impaired clinical groups while retaining a strong relationship to functionally defined brain 
networks. The connectome25 derived from task-free fMRI is robust, reproducible and capable of 
generating brain networks analogous to other physiological techniques such as EEG or 
Magnetoencephalography26. 
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We used task-free fMRI to assess people with genetic frontotemporal dementia and their first-
degree relatives in whom approximately half carry the familial gene abnormality. Our cohort 
included mutations or expansions in the three major genes associated with FTD: PGRN, MAPT, 
C9orf72. We tested the hypothesis that, prior to the age of symptom onset in genetic FTD, 
functional network resilience arises from the maintenance of an efficient network topology 
preserving cognitive function in the context of progressive pathology assessed by brain volume loss. 
From the age of symptom onset we would expect the loss of functional network resilience, with a 
decline in network efficiency and connectivity in relation to both brain volume loss and cognitive 
function. 
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Subjects were recruited as part of the multi-center international Genetic Frontotemporal Dementia 
Initiative (GENFI) and underwent a standardised assessment3. The age of expected symptom onset 
was defined as the mean within each family, which is significantly correlated among affected 
relatives3. Echo-Planar Imaging and Magnetization Prepared Rapid Gradient Echo (MPRAGE) 
were acquired at each centre. Analogous imaging sequences were acquired at each GENFI study 
site accommodating different manufacturers and field strengths (1.5T and 3T). Echo-planar images 
were acquired over at least 300s with a median of 315s (IQR 309-440) and had a median Repetition 
Time (TR) of 2200ms (2200ms-3000ms), echo time of 30ms, in-plane resolution of 2.75x2.75mm 
(2.75-3.31 x 2.75-3.31), slice thickness of 3.3mm (3.0-3.3). MPRAGE images were obtained during 
the same acquisition. 
 
Image preprocessing used MPRAGE images to generate a transformation to register images to 
Montreal Neurological Institute (MNI) standard space via a study-specific template using 
Diffeomorephic Anatomical Registration Through Exponentiated Lie algebra (DARTEL) 
implemented in SPM12 (www.fil.ion.ucl.ac.uk/spm/software/spm12/). This transformation was 
applied to co-registered functional images. Functional image pre-processing was performed using 
the brainwavelet pipeline (www.brainwavelet.org) including slice-time correction, regression of 
cerebrospinal fluid, white matter, movement parameters and their derivatives, and despiking using a 
wavelet algorithm. Identification of motion outliers for exclusion used the spike percentage 
threshold, defined as the percentage of the timeseries in which spikes were identified during the 
wavelet despiking process. The spike percentage threshold was set at 10% at which level the 
removal of subjects did not significantly change the connection strength measured across all 
subjects. 
 
Each subject's brain volume was parcellated in to 500 approximately equally sized regions using a 
centroidal Voronoi tessalation27. Of the 500 regions, 29 were insufficiently covered in some or all 
subjects, leaving 471 regions for further analysis. The fMRI signal timeseries within each parcel 
was bandpass filtered using a wavelet scale of 0.0675-0.125Hz. 
 
Graph theoretical analysis was applied to network connectivity, the wavelet cross-correlation was 
used as a measure of the strength of each connection. Networks were then analysed in terms of 
connection strength, efficiency and connectedness. Graph analysis used the Maybrain package 
(github.com/RittmanResearch/maybrain). We defined connection strength as the sum of nodal 
connection strength (also called weighted degree) values of all the network's nodes. To capture the 
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defined as the sum of the inverse path lengths for all nodes in a network. The analogous nodal 
measure of closeness centrality is defined as the sum of the path lengths for each node to all other 
network nodes. Efficiency measures were normalised against the mean value generated from 500 
graphs with an identical degree distribution and random connections. We assessed atrophy by 
calculating the percentage brain volume or regional volume compared to the total intracranial 
volume. Hubs were defined in the gene negative group as brain regions with connection strength 
two standard deviations greater than other regions. 
 
Because network measures are not independent, we did not apply correction for multiple 
comparisons. Group comparisons between the gene carrier and FTD group were performed for each 
network measure using a mixed effects linear model with diagnostic group as the main effect, age as 
a dependent variable, and scan site and gene type as random variables using the lmer package in R. 
We included the gene negative group in all models to properly estimate the effect of age. We then 
assessed group differences by specifying an appropriate contrast between the gene carrier group and 
FTD groups. The Sattherthwaite estimate of effective degrees of freedom enabled calculation of 
significance values. In order to assess the relationship between estimated age at onset and network 
measures we extended the linear mixed effects model by including an interaction term between the 
diagnostic group and estimated time to symptom onset. 
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Twenty-nine people with genetic FTD were recruited (12 C9orf72, 11 MAPT, 6 PGRN), 70 
unaffected relatives carrying the same mutation we will refer to as “gene carriers” (17 C9orf72, 13 
MAPT, 40 PGRN) and 86 relatives without the mutation, referred to as “gene negative”. During 
image processing 13 subjects were removed because of excessive motion, 5 with FTD (1 C9orf72, 2 
MAPT, 2 PGRN), 2 gene carriers (2 PGRN) and 6 gene negative. The remaining 172 subjects were 
taken forward for analysis: 24 FTD, 68 gene carriers, 80 gene negative. Demographic information is 
shown in table 1. The FTD clinical syndromes were: behavioural variant FTD n=20, FTD-Motor 
Neuron Disease n=1, Primary Progressive Aphasia n=2, dementia not otherwise specified=1. 
 
3.1 Differences in network connectivity and efficiency between groups 
To assess the difference in global network properties between the gene negative, gene carriers and 
FTD groups, brain networks were assessed for connection strength and global efficiency, shown in 
figure 1. The FTD group (mean connection strength 121.8) was less well connected compared with 
gene carrier (149.4, p=0.01) and gene negative groups (147.1, p=0.02). Gene carriers (mean global 
efficiency 0.88)  had a higher global efficiency than the gene negative group (0.86, p=0.004) but 
there was no differences in global efficiency in any other comparison (FTD 0.86). We found similar 
regional reduction in connectivity in frontal lobes, temporal lobes, occipital lobes, and cingulate 
cortices, cerebellum and insula cortices in the FTD group compared with gene carriers; increased 
efficiency (closeness centrality) in all brain regions in the gene carrier group compared with the 
gene negative group, and reduced efficiency in the occipital cortex in FTD compared with gene 
carriers; see figures 2 and 3 and eTable 1. 
 
To assess whether regional network properties would influence change in network properties we 
examined the most highly connected ‘hub’ regions. By definition, hubs were more connected than 
non-hubs; however the difference in connection strength between hubs and non-hubs was 
significantly smaller in the FTD group (p=0.02), suggesting that hubs were weaker in the FTD 
group. The difference in efficiency measured by closeness centrality between hubs and non-hubs 
was abolished in the FTD group (effect size 0.0025, p=0.5) compared with gene carriers (effect size 
-0.01, p<0.00001); the difference between these effects being significant (p=0.001). 
 
3.2 Disease progression and network measures 
To test the relationship between between network measures and disease progression we began by 
estimating the temporal relationships between network measures and symptom onset. There were 
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no simple linear relationships of time to the estimated age of symptom onset with connection 
strength (p=0.6) or global efficiency (p=0.17). 
 
We then tested whether there may be a non-linear decline in network properties. We assessed 
whether a breakpoint existed in the relationship between estimated time to symptom onset and 
network measures at the estimated time of symptom onset using piecewise regression analysis. 
There was no significant breakpoint in network measures at the estimated time of onset in 
connection strength for the whole brain (p=0.9) or any brain region, see figure 2 and eResults. For 
global efficiency we found a significant breakpoint (p=0.009) suggesting that global efficiency 
starts to decline at the time of symptom onset, see figure 1. We saw similar breakpoints for 
efficiency in the frontal lobes, parietal lobes, occipital lobes and cingulate cortex, see figure 3 and 
eResults. These results suggest that network topology declines in a dramatic fashion at the point of 
transition from pre-sympomatic to symptomatic FTD. 
 
3.3 Functional network resilience to brain atrophy 
We assessed whether connection strength and network efficiency was associated with brain volume 
loss, see figure 4. Connection strength correlated with reduced brain volume in the FTD group 
(r=0.47, p=0.0002). This correlation differed significantly from the non-significant relationship 
between connection strength in the gene carriers group (r=0.031, p=0.6, difference between 
interactions (p=0.001). Similar differences were seen in the frontal, temporal and parietal lobes, see 
fig 4 and eResults. 
 
There was no relationship between global efficiency in the FTD group and whole brain atrophy 
(p=0.2), and no interaction between the FTD group and gene carriers on the relationship between 
global efficiency and whole brain atrophy (p=0.3). No brain regions demonstrated a relationship 
between global efficiency and whole brain or regional atrophy. 
 
3.4 Relationship between network properties and cognitive function 
Clinical scores are shown in table 2. As expected there were no significant differences between gene 
negative and gene carriers, whereas all measures were markedly impaired in the FTD group 
compared to the gene carrier group (p <0.0001 for all comparisons). The relationship between 
clinical test scores and years from expected onset was not clearly linear in the FTD group, 
suggestive of an acute decline in ability at diagnosis rather than a continuous linear association. 
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and Trails A (p=0.0002) and a difference in the relationships between the FTD and gene carrier 
groups for both cognitive measures  (MMSE: p=0.004, Trails A: p=0.0006), although there were 
possible ceiling effects in the gene carrier group on both these tests, see eTable 3 for full results. 
 
For digit span and verbal fluency, we observed a relationship between connection strength and test 
performance across both FTD and gene carrier group combined, but no difference in the 
relationship between groups: digit span (p=0.03), categorical verbal fluency (p=0.03) and letter 
verbal fluency (p=0.01). This suggests that a loss of connectivity prior to the onset of clinical 
symptoms is relevant to declining cognitive performance in these tests. Of note, we included age as 
a covariate in these models, to reduce the likelihood that age explained these results. 
 
Higher global efficiency was associated with better performance on the MMSE in the gene carrier 
group (p<0.001), but there was no such relationship in the FTD group (p=0.053); the difference in 
the effect between groups was significant (p=0.049). There was a decline in performance on Trails 
B with reduced global efficiency in the FTD group (p=0.02), although the difference in this 
relationship from the gene carrier group did not reach significance (p=0.1). There was no other 
significant relationship between global efficiency and cognitive performance. 
 
Finally, we tested whether region specific measures might correlate with cognitive scores, shown in 
eTable 3. Both MMSE and Trials A demonstrated consistent relationships with connection strength 
in FTD and significant difference from the gene carrier group (occipital lobe, temporal lobe, insula, 
cingulate, hippocampus) similar to the whole brain results. However, these tests demonstrate 
marked ceiling effects which may limit the interpretation of these results. 
 
Worse performance on forward digit span was related to a loss of connection strength in the parietal 
lobe in FTD, and in the Boston naming test with loss of connection strength in the occipital lobe. 
Both these relationships differed significantly from the gene carrier group; see eTable 3. 
 
For the network efficiency measure of closeness centrality, the Trials B test that requires significant 
working memory was related to network efficiency in the hippocampus, and this relationship 
differed significantly from the gene carrier group; see eTable 3. Similar to connection strength, 
there was a relationship between efficiency and MMSE score, and a significant difference in this 
relationship compared to the gene carrier group in the occipital lobe, cerebellum and insula. 
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of connection strength and efficiency may be relevant to specific cognitive functions, particularly in 
the Trails B, forward digit span and Boston naming tasks. 
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We demonstrate that the brain can function normally for cognitive well-being despite substantial 
pre-symptomatic neurodegenerative disease if it can maintain efficient information processing 
through functional connections, but that brain network efficiency declines sharply around the time 
of symptom onset. The loss of network efficiency is most severe in highly connected hub regions 
and regional changes in network efficiency are associated with worsening of cognitive deficits 
associated with FTD. We propose that interventions during the crucial pre-symptomatic period of 
neurodegenerative disease could be effective if they promote the maintenance or resilience of the 
brain’s intrinsically efficient arrangement of functional network connections. 
 
Our findings challenge the concept that functional deficits mirror structural change early in the 
disease process. This is not to say that structural changes are irrelevant to brain function28,29. 
However, many years before symptom onset there can be gross changes in brain structure and CSF 
biomarkers that indicate an active neuropathological processes and atrophy, both in familial 
neurodegenerative disease1,3,30,31 and in sporadic disease such as early Alzheimer’s disease and 
MCI32–34. We therefore tested whether resilience of brain network organisation can explain the 
discrepancy between changes in structure and cognitive function. 
 
The brain’s resilience to structural change in pre-symptomatic disease might depend on topological 
resilience or active compensation. We propose that topological resilience provides a greater 
contribution for several reasons. In common with many ecological and man-made networks, the 
brain’s network has a ‘small world’ configuration that balances the metabolic costs of long distance 
connections between any two points in the network (path length) and shared connections between 
locally connected nodes (clustering)7,8,35. Highly connected hubs are essential to small world 
networks. In the brain they are metabolically active36,37 and play a role in efficient integration of 
information between regions5,6,38,39. The presence of hubs mean that small world networks are 
resilient to targeted and random network attacks7, even if the hubs themselves are more prone to the 
effects of neuropathology40. 
 
The concept of functional network resilience is closely linked and overlapping with the concepts of 
cognitive reserve, brain reserve and brain maintenance41. Our definition of functional resilience is 
closely aligned with cognitive reserve, which is a multifaceted concept that educational, social and 
exercise lead to maintained cognitive abilities in the context of ageing or neurodegeneration42. 
There is preliminary evidence that cognitive reserve (at least as estimated from academic and 
occupational attainments) ameliorates the cognitive impact of neurodegenerative disease, or against 
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reaching the threshold for diagnosis of neurodegenerative disease43,44. Indeed, higher cognitive 
reserve (estimated by years of education) is associated with slower atrophy and later symptom onset 
in familial FTD associated with TPD-4345. This effect is moderated by genetic factors (TMEM106B 
genotype), with many questions remaining as to the mechanisms of effect of cognitive reserve. It is 
likely that functional brain imaging reflects aspects of cognitive reserve46, but these are not yet well 
established. It is beyond the scope of this study to identify the effect of education on functional 
network resilience, or the genetic moderators of such an effect. As a cross-section study, possible 
cohort-effects mean that differences in cognitive reserve between younger and older gene carriers 
cannot wholly be ruled out as a contributor to the maintenance of global efficiency we observe. 
However, the stability of global efficiency in the years leading up to symptom onset (figure 1), 
averages across subjects with differences in education and occupation reserve at any given range of 
years from expected onset of symptoms.  
 
We found a complex relationship between functional connectivity and brain volume loss. In the 
FTD group a relatively small reduction in connection strength was correlated with a much greater 
reduction in brain volume, which was not the case in presymptomatic or gene negative participants. 
One intriguing possibility is that premorbid connection strength influences the rate of volume loss 
in disease. This echoes previous studies showing that specific brain network and connectivity 
patterns influence the pattern of brain atrophy and neuropathology in a range of neurodegenerative 
diseases40,47. 
 
We assessed whether clinical measures of disease would help us to relate domains of cognitive 
function to the changes we observed in functional network resilience. In general, the associations 
were not strong, which may relate to the global nature of the network measures we assessed in 
comparison to the more specific and localisable clinical measures. However, we identified a decline 
in verbal fluency in relation to connection strength that may reflect subtle pre-symptomatic 
cognitive impairment. We found relationships between local measures of network connectivity with 
the Boston naming test in the occipital lobe and digit span in the parietal lobe. We are cautious 
about interpreting these results given the relatively weak associations and the seeming mismatch in 
localisation. It is likely that more local or network-specific measures of network integrity would be 
better associated with cognitive tests. 
 
Our study has several important limitations. Cohorts of genetic dementia are rare and despite a 
coordinated multinational recruitment effort the number of subjects is relatively small, although 
larger than many comparable studies of functional neuroimaging in dementia. This study was cross-
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sectional rather than longitudinal, therefore our inference of change over time are based on the 
assumption of a similar starting value and rate of change between individuals. fMRI has been often 
open to criticism as a technique since it measures an indirect measure of Blood Oxygen Level 
Dependent as a surrogate for neuronal activity48; it has a poor frequency resolution, and it may be 
affected by movement of subjects within the scanner. Despite these limitations it has proven to be a 
valuable and useful tool to interrogate brain networks and produces network data comparable to 
other techniques such as EEG or MEG26. There were more females in the FTD group compared to 
males, although comparison across the three groups (gene negative, carriers and FTD) was not 
significant. Whilst a more balanced cohort would be ideal, we consider that the effects of FTD 
would outweigh any subtle gender effects, and gender differences would not explain the differences 
between gene carriers and gene negative participants. 
 
5. Conclusions 
We propose that the maintenance of functional brain networks underlies the resilience of the brain 
to neurodegenerative pathology in the presence of significant neuronal loss. We suggest that 
resilient topological organisation rather than active compensation is the main contributor to this 
resilience. Our findings suggest a window of opportunity to intervene in the pre-symptomatic stage 
of neurodegenerative diseases, including treatment strategies that promote efficiency and 
integration in the brain’s functional brain networks even in the presence of progressive atrophy. 
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Figure legends 
Figure 1: 
Connection strength is reduced in genetic FTD compared to asymptomatic gene carrying 
relatives 
Differences between the genetic FTD group and pre-symptomatic gene carrying relatives 
demonstrate reduced connection strength using a mixed effects linear model (p=0.01) with no 
difference in global efficiency (p=0.2). The results for individual genes are shown for completeness, 
though we would be cautious in interpreting these results given the small group sizes. Using a 
simple t-test, there was significantly reduced connection strength in the PGRN FTD group 
(p<0.00001) and global efficiency in the MAPT FTD group (p=0.02). In order to assess whether 
there was a non-linear relationship between network measures and time to the estimated age of 
symptom onset, we performed discontinuous breakpoint analysis. There was a significant 
breakpoint in global efficiency (p=0.009), but not for connection strength (p=0.9). Significance 
values: *<0.05, **<0.01, ***<0.001, ****<0.0001. 
 
Figure 2: 
Although relevant brain regions demonstrate reduced connectivity in FTD there is no 
significant change at symptom onset 
For each brain region the difference in connection strength between gene carrier and FTD groups 
are presented, significant values were calculated using a mixed-effects linear regression model. 
There were significant differences in the frontal, temporal, occipital, cingulate and insula cortices 
(see eResults). However, no brain region demonstrated a significant breakpoint in connect strength 
at the age of symptom onset (using a piecewise linear regression model). Significance values: 
*<0.05, **<0.01, ***<0.001, ****<0.0001. 
 
Figure 3: 
Brain regions demonstrate both reduced efficiency in FTD and a significant decline in 
efficiency beginning at symptom onset 
for each brain region the difference in closeness centrality between gene carrier and FTD groups are 
presented, significant values were calculated using a mixed-effects linear regression model (see 
eResults). There were significant differences in the frontal, temporal, occipital, cerebellar and 
cingulate cortices. In contrast to the connectivity results, there were significant breakpoints in 
closeness centrality at the age of symptom onset in frontal, temporal, parietal, occipital and 
cingulate cortices. These findings suggest that an efficient brain structure is maintained in these 
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breaks down thereafter. 
 
Figure 4: 
Whole brain atophy and the atrophy in relevant brain regions is correlated with the loss of 
connectivity only after symptom onset 
we examined whether the volume of the whole brain and brain regions were associated with loss of 
connection strength. There was a relationship between volume and connection strength in the whole 
brain (p=0.0002), frontal lobe (p=0.005) and temporal lobes (p<0.00001) in the FTD group only 
and not in the gene carrier group; in each case there was a significant difference between the 
relationship in the FTD group and gene carrier groups (whole brain p=0.001; frontal lobes p=0.02; 
temporal lobes p=0.0002). Significance values: *<0.05, **<0.01, ***<0.001, ****<0.0001. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Tables 
  P value Gene negative Gene carriers FTD 
Age, years (sd) <0.00001 47.8 (15.5) 44.5 (12.3) 62.4 (8.6) 
Sex (M/F) ns* 49(61%) / 31(39%) 40(59%) / 28(41%) 7(29%) / 17(71%) 
Hand (L/R/Ambi) ns 74(93%) / 5(6%) / 1 
(1%) 
58(85%) / 8(12%) / 2 
(3%)  
22(92%) / 2(8%) / 0 
(0%) 
Education, years (sd) ns 13.7 (3.5) 13.8 (3.2) 12.2 (4.5) 
 
Table 1: Demographics for subjects included in the analysis. For parametric data analysis of 
variance was used and we report the mean, and the standard deviation in parentheses. For 
categorical data the chi-square test was used and we report the numbers in each category. As 
expected, people with FTD were older than both gene carriers (p<0.00001) and gene negative 
subjects (p<0.00001). *Although sex differences were not significant when tested across all three 
groups, pairwise tests confirmed that there were fewer men in the FTD patient group compared with 
both the gene carrier (p=0.02) and gene negative (p=0.01) groups. FTD = frontotemporal dementia, 
ns = non-significant >0.1. 
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 Gene negative Gene carriers FTD 
MMSE 29.2 (1.4) 29.1 (1.5) 22.3 (6.3) 
Log Immediate Memory 0.08 (1.02) 0.08 (0.84) -2.07 (1.1) 
Log Delayed Memory 0.08 (0.98) -0.04 (0.77) -2.08 (0.99) 
Forward Digit Span 0.02 (0.97) -0.03 (1) -1.21 (1.44) 
Backwards Digit Span 0.01 (0.99) -0.12 (0.9) -1.71 (1.19) 
Trails A 0.2 (0.91) 0.29 (0.58) -2.49 (2.49) 
Trails B 0.16 (0.91) 0.24 (0.88) -2.49 (1.34) 
Digit Symbol Task 0.25 (1.12) 0.27 (0.95) -1.98 (0.89) 
Boston Naming Task 0.15 (0.88) 0.03 (1.1) -3.53 (2.66) 
Verbal Fluency (Category) 0.14 (1.02) 0.16 (0.91) -2.04 (0.9) 
Verbal Fluency (Letter) -0.06 (1.01) -0.05 (1.2) -2.64 (0.96) 
Block Design Task 0.01 (1) 0.17 (0.98) -2.05 (0.97) 
 
Table 2: Mean clinical scores for each group with standard deviation shown in parentheses. The raw 
MMSE score is shown and z-score for other measures. These scores are corrected for language, but 
not for other demographics. 
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*GENFI consortium members:  
• Sónia Afonso - Instituto Ciencias Nucleares Aplicadas a Saude, Universidade de Coimbra, 
Coimbra, Portugal; sgafonso90@hotmail.com 
•     Maria Rosario Almeida - Faculty of Medicine, University of Coimbra, Coimbra, Portugal; 
mralmeida2008@gmail.com 
•     Sarah Anderl-Straub – Department of Neurology, University of Ulm, Ulm, Germany; 
sarah.straub@uni-ulm.de 
•     Christin Andersson - Department of Clinical Neuroscience, Karolinska Institutet, 
Stockholm, Sweden; christin.andersson@karolinska.se 
•     Anna Antonell - Alzheimer’s disease and Other Cognitive Disorders Unit, Neurology 
Service, Hospital Clínic, Barcelona, Spain; antonell@clinic.cat 
•     Silvana Archetti – Biotechnology Laboratory, Department of Diagnostics, Spedali Civili 
Hospital, Brescia, Italy; archetti.s@tiscali.it 
•     Andrea Arighi - Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 
Neurodegenerative Diseases Unit, Milan, Italy; University of Milan, Centro Dino Ferrari, 
Milan, Italy; andrea.arighi@yahoo.it 
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Service, Hospital Clínic, Barcelona, Spain; mbalasa@clinic.ub.es 
•     Myriam Barandiaran - Cognitive Disorders Unit, Department of Neurology, Donostia 
University Hospital, San Sebastian, Gipuzkoa, Spain; euroscience Area, Biodonostia 
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University of Tübingen, Tübingen, Germany; benjamin.bender@med.uni-tuebingen.de 
•     Luisa Benussi - Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San 
Giovanni di Dio Fatebenefratelli, Brescia, Italy; lbenussi@fatebenefratelli.eu  only if DF1 or 
2 data included 
•     Valentina Bessi - Department of Neuroscience, Psychology, Drug Research, and Child 
Health, University of Florence, Florence, Italy; only if DF1 or 2 data included 
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•     Martina Bocchetta – Dementia Research Centre, Department of Neurodegenerative 
Disease, UCL Institute of Neurology, Queen Square, London, UK; m.bocchetta@ucl.ac.uk 
•     Sergi Borrego-Ecija - Alzheimer’s disease and Other Cognitive Disorders Unit, 
Neurology Service, Hospital Clínic, Barcelona, Spain; borrego@clinic.cat 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
•     Jose Bras - Dementia Research Institute, Department of Neurodegenerative Disease, UCL 
Institute of Neurology, Queen Square, London, UK; j.bras@ucl.ac.uk 
•     Rose Bruffaerts - Laboratory for Cognitive Neurology, Department of Neurosciences, KU 
Leuven, Leuven, Belgium; rose.bruffaerts@uzleuven.be 
•     Paola Caroppo -Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy; 
Paola.Caroppo@istituto-besta.it  
•     David Cash – Dementia Research Centre, Department of Neurodegenerative Disease, 
UCL Institute of Neurology, Queen Square, London, UK; d.cash@ucl.ac.uk 
•     Miguel Castelo-Branco - Faculty of Medicine, University of Coimbra, Coimbra, Portugal; 
mcbranco@fmed.uc.pt 
•     Rhian Convery – Dementia Research Centre, Department of Neurodegenerative Disease, 
UCL Institute of Neurology, Queen Square, London, UK; rhian.convery.16@ucl.ac.uk 
•     Thomas Cope – Department of Clinical Neuriscience, University of Cambridge, 
Cambridge, UK; tec31@medschl.cam.ac.uk 
•     Maura Cosseddu - Centre for Neurodegenerative Disorders, Neurology Unit, Department 
of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; 
maura.cosseddu@gmail.com 
•     María de Arriba - Neuroscience Area, Biodonostia Health Research Insitute, San 
Sebastian, Gipuzkoa, Spain; dearribamaria@gmail.com 
•     Giuseppe Di Fede -Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy; 
Giuseppe.DiFede@istituto-besta.it 
•     Zigor Díaz - CITA Alzheimer, San Sebastian, Gipuzkoa, Spain; zdiaz@cita-alzheimer.org 
•     Katrina M Dick – Dementia Research Centre, Department of Neurodegenerative Disease, 
UCL Institute of Neurology, Queen Square, London UK; k.dick@ucl.ac.uk 
•     Diana Duro - Faculty of Medicine, University of Coimbra, Coimbra, Portugal; 
diana.duro@gmail.com 
•     Chiara Fenoglio - Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 
Neurodegenerative Diseases Unit, Milan, Italy; University of Milan, Centro Dino Ferrari, 
Milan, Italy; chiara.fenoglio@unimi.it 
•     Camilla Ferrari - Department of Neuroscience, Psychology, Drug Research, and Child 
Health, University of Florence, Florence, Italy; only if DF1 or 2 data included 
•     Catarina B. Ferreira -Laboratory of Neurosciences, Institute of Molecular Medicine, 
Faculty of Medicine, University of Lisbon, Lisbon, Portugal; 
catarina.ferreira@medicina.ulisboa.pt 
•     Toby Flanagan -Faculty of Biology, Medicine and Health, Division of Neuroscience and 
Experimental Psychology, University of Manchester, Manchester, UK; 
toby.flanagan@manchester.ac.uk  
•     Nick Fox – Dementia Research Centre, Department of Neurodegenerative Disease, UCL 
Institute of Neurology, Queen Square, London, UK; n.fox@ucl.ac.uk 
•     Morris Freedman -Baycrest Health Sciences, Rotman Research Institute, University of 
Toronto, Toronto, Canada; mfreedman@baycrest.org 
•     Giorgio Fumagalli -Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 
Neurodegenerative Diseases Unit, Milan, Italy; University of Milan, Centro Dino Ferrari, 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPTMilan, Italy; Department of Neurosciences, Psychology, Drug Research and Child Health 
(NEUROFARBA), University of Florence, Florence, Italy; giorgiofumagalli@hotmail.com 
•     Alazne Gabilondo -Neuroscience Area, Biodonostia Health Research Insitute, San 
Sebastian, Gipuzkoa, Spain; alazne.gabilondolopez@osakidetza.eus 
•     Roberto Gasparotti - Neuroradiology Unit, University of Brescia, Brescia, Italy; 
roberto.gasparotti@gmail.com 
•     Serge Gauthier -Alzheimer Disease Research Unit, McGill Centre for Studies in Aging, 
Department of Neurology & Neurosurgery, McGill University, Montreal, Québec, Canada; 
serge.gauthier@mcgill.ca 
•     Stefano Gazzina -Centre for Neurodegenerative Disorders, Neurology Unit, Department 
of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; 
stefanogazzina@alice.it 
•     Roberta Ghidoni - Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San 
Giovanni di Dio Fatebenefratelli, Brescia, Italy; rghidoni@fatebenefratelli.eu  only if DF1 
or 2 data included 
•     Giorgio Giaccone -Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy; 
Giorgio.Giaccone@istituto-besta.it 
•     Ana Gorostidi - Neuroscience Area, Biodonostia Health Research Insitute, San Sebastian, 
Gipuzkoa, Spain; ana.gorostidipagola@osakidetza.eus 
•     Caroline Greaves – Dementia Research Centre, Department of Neurodegenerative 
Disease, UCL Institute of Neurology, Queen Square, London, UK; 
caroline.greaves.14@ucl.ac.uk 
•     Rita Guerreiro - Dementia Research Institute, Department of Neurodegenerative Disease, 
UCL Institute of Neurology, Queen Square, London, UK; r.guerreiro@ucl.ac.uk 
•     Carolin Heller – Dementia Research Centre, Department of Neurodegenerative Disease, 
UCL Institute of Neurology, Queen Square, London, UK; c.heller@ucl.ac.uk 
•     Tobias Hoegen -Neurologische Klinik, Ludwig-Maximilians-Universität München, 
Munich, Germany; tobias.hoegen@med.uni-muenchen.de 
•     Begoña Indakoetxea - Cognitive Disorders Unit, Department of Neurology, Donostia 
University Hospital, San Sebastian, Gipuzkoa, Spain; Neuroscience Area, Biodonostia 
Health Research Insitute, San Sebastian, Gipuzkoa, Spain; 
begona.indacoecheajuanbeltz@osakidetza.eus 
•     Vesna Jelic - Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden; 
vesna.jelic@ki.se 
•     Lize Jiskoot - Department of Neurology, Erasmus Medical Center, Rotterdam, 
Netherlands; l.c.jiskoot@erasmusmc.nl 
•     Hans-Otto Karnath - Division of Neuropsychology, Hertie-Institute for Clinical Brain 
Research and Center of Neurology, University of Tübingen, Tübingen, Germany; 
karnath@uni-tuebingen.de 
•     Ron Keren -The University Health Network, Toronto Rehabilitation Institute, Toronto, 
Canada; Ron.Keren@uhn.ca 
•     Maria João Leitão - Centre of Neurosciences and Cell Biology, Universidade de Coimbra, 
Coimbra, Portugal; jajao86@gmail.com 
•     Albert Lladó - Alzheimer’s disease and Other Cognitive Disorders Unit, Neurology 
Service, Hospital Clínic, Barcelona, Spain; allado@clinic.ub.es 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
•     Gemma Lombardi - Department of Neuroscience, Psychology, Drug Research and Child 
Health, University of Florence, Florence, Italy; gemmalomb@gmail.com   only if DF1 or 2 
data included 
•     Sandra Loosli -Neurologische Klinik, Ludwig-Maximilians-Universität München, 
Munich, Germany; sandra.loosli@med.uni-muenchen.de 
•     Carolina Maruta -Laboratory of Language Research, Centro de Estudos Egas Moniz, 
Faculty of Medicine, University of Lisbon, Lisbon, Portugal; carolmaruta@gmail.com 
•     Simon Mead - MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute 
of Neurology, Queen Square, London, UK; s.mead@prion.ucl.ac.uk  
•     Lieke Meeter - Department of Neurology, Erasmus Medical Center, Rotterdam, 
Netherlands; h.meeter@erasmusmc.nl 
•     Gabriel Miltenberger - Faculty of Medicine, University of Lisbon, Lisbon, Portugal; 
gmiltenyi@medicina.ulisboa.pt 
•     Rick van Minkelen - Department of Clinical Genetics, Erasmus Medical Center, 
Rotterdam, Netherlands; r.vanminkelen@erasmusmc.nl 
•     Sara Mitchell - Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, 
University of Toronto, Toronto, Canada; sara.mitchell@sunnybrook.ca 
•     Benedetta Nacmias - Department of Neuroscience, Psychology, Drug Research and Child 
Health, University of Florence, Florence, Italy; benedetta.nacmias@unifi.it  only if DF1 or 2 
data included 
•     Mollie Neason – Dementia Research Centre, Department of Neurodegenerative Disease, 
UCL Institute of Neurology, Queen Square, London, UK; m.neason@ucl.ac.uk 
•     Jennifer Nicholas - Department of Medical Statistics, London School of Hygiene and 
Tropical Medicine, London, UK; Jennifer.Nicholas@lshtm.ac.uk 
•     Linn Öijerstedt - Department of Geriatric Medicine, Karolinska University Hospital-
Huddinge, Stockholm, Sweden; linn.oijerstedt@ki.se 
•     Jaume Olives - Alzheimer’s disease and Other Cognitive Disorders Unit, Neurology 
Service, Hospital Clínic, Barcelona, Spain; jolives@clinic.ub.es 
•     Alessandro Padovani -Centre for Neurodegenerative Disorders, Neurology Unit, 
Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; 
alessandro.padovani@unibs.it  
•     Jessica Panman – Department of Neurology, Erasmus Medical Center, Rotterdam, 
Netherlands; j.panman@erasmusmc.nl  
•     Janne Papma - Department of Neurology, Erasmus Medical Center, Rotterdam; 
j.papma@erasmusmc.nl 
•     Michela Pievani - Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San 
Giovanni di Dio Fatebenefratelli, Brescia, Italy; mpievani@fatebenefratelli.eu  only if DF1 
or 2 data included 
•     Yolande Pijnenburg -Amsterdam University Medical Centre, Amsterdam VUmc, 
Amsterdam, Netherlands; YAL.Pijnenburg@vumc.nl 
•     Enrico Premi -Centre for Neurodegenerative Disorders, Neurology Unit, Department of 
Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; 
zedtower@gmail.com 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
•     Sara Prioni -Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy; 
Sara.Prioni@istituto-besta.it 
•     Catharina Prix -Neurologische Klinik, Ludwig-Maximilians-Universität München, 
Munich, Germany; catharina.prix@med.uni-muenchen.de 
•     Rosa Rademakers as London Ontario geneticist - Department of Neurosciences, Mayo 
Clinic, Jacksonville, Florida, USA; Rademakers.Rosa@mayo.edu 
•     Veronica Redaelli -Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy; 
Veronica.Redaelli@istituto-besta.it 
•     Ekaterina Rogaeva -Tanz Centre for Research in Neurodegenerative Diseases, University 
of Toronto, Toronto, Canada; ekaterina.rogaeva@utoronto.ca 
•     Pedro Rosa-Neto -Translational Neuroimaging Laboratory, McGill Centre for Studies in 
Aging, McGill University, Montreal, Québec, Canada; pedro.rosa@mcgill.ca 
•     Giacomina Rossi - Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy; 
Giacomina.Rossi@istituto-besta.it  
•     Martin Rosser – Dementia Research Centre, Department of Neurodegenerative Disease, 
UCL Institute of Neurology, Queen Square, London, UK; m.rossor@ucl.ac.uk 
•     Beatriz Santiago - Neurology Department, Centro Hospitalar e Universitario de Coimbra, 
Coimbra, Portugal; hbmcsantiago@hotmail.com 
•     Elio Scarpini -Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 
Neurodegenerative Diseases Unit, Milan, Italy; University of Milan, Centro Dino Ferrari, 
Milan, Italy; elio.scarpini@unimi.it 
•     Sonja Schönecker - Neurologische Klinik, Ludwig-Maximilians-Universität München, 
Munich, Germany; sonja.schoenecker@med.uni-muenchen.de 
•     Elisa Semler -Department of Neurology, University of Ulm, Ulm; elisa.semler@uni-
ulm.de 
•     Rachelle Shafei – Dementia Research Centre, Department of Neurodegenerative Disease, 
UCL Institute of Neurology, Queen Square, London, UK; r.shafei@ucl.ac.uk 
•     Christen Shoesmith - Department of Clinical Neurological Sciences, University of 
Western Ontario, London, Ontario, Canada; christen.shoesmith@lhsc.on.ca 
•     Miguel Tábuas-Pereira - Neurology Department, Centro Hospitalar e Universitario de 
Coimbra, Coimbra, Portugal; miguelatcp@gmail.com 
•     Mikel Tainta - Neuroscience Area, Biodonostia Health Research Insitute, San Sebastian, 
Gipuzkoa, Spain; mikeltainta@gmail.com 
•     Ricardo Taipa - Neuropathology Unit and Department of Neurology, Centro Hospitalar do 
Porto - Hospital de Santo António, Oporto, Portugal; ricardotaipa@gmail.com 
•     David Tang-Wai -The University Health Network, Krembil Research Institute, Toronto, 
Canada; David.Tang-Wai@uhn.ca 
•     David L Thomas - Neuroimaging Analysis Centre, Department of Brain Repair and 
Rehabilitation, UCL Institute of Neurology, Queen Square, London, UK; 
d.thomas@ucl.ac.uk 
•     Hakan Thonberg - Center for Alzheimer Research, Division of Neurogeriatrics, 
Karolinska Institutet, Stockholm, Sweden; hakan.thonberg@karolinska.se  
•     Carolyn Timberlake – Department of Clinical Neurosciences, University of Cambridge, 
Cambridge, UK; cmc38@medschl.cam.ac.uk  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
•     Pietro Tiraboschi -Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy; 
Pietro.Tiraboschi@istituto-besta.it 
•     Philip Vandamme - Neurology Service, University Hospitals Leuven, Belgium; 
Laboratory for Neurobiology, VIB-KU Leuven Centre for Brain Research, Leuven, 
Belgium; philip.vandamme@uzleuven.be 
•     Mathieu Vandenbulcke - Geriatric Psychiatry Service, University Hospitals Leuven, 
Belgium; Neuropsychiatry, Department of Neurosciences, KU Leuven, Leuven, Belgium; 
mathieu.vandenbulcke@uzleuven.be 
•     Michele Veldsman - Nuffield Department of Clinical Neurosciences, Medical Sciences 
Division, University of Oxford, Oxford, UK; michele.veldsman@ndcn.ox.ac.uk 
•     Ana Verdelho - Department of Neurosciences and Mental Health, Centro Hospitalar 
Lisboa Norte - Hospital de Santa Maria & Faculty of Medicine, University of Lisbon, 
Lisbon, Portugal; averdelho@medicina.ulisboa.pt 
•     Jorge Villanua - OSATEK, University of Donostia, San Sebastian, Gipuzkoa, Spain; 
jorgealbertovillanuabernues@gmail.com 
•     Jason Warren – Dementia Research Centre, Department of Neurodegenerative Disease, 
UCL Institute of Neurology, Queen Square, London, UK; jason.warren@ucl.ac.uk 
•     Carlo Wilke -Department of Neurodegenerative Diseases, Hertie-Institute for Clinical 
Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany; 
Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany; carlo.wilke@uni-
tuebingen.de 
•     Ione Woollacott – Dementia Research Centre, Department of Neurodegenerative Disease, 
UCL Institute of Neurology, Queen Square, London, UK; ione.woollacott@ucl.ac.uk 
•     Elisabeth Wlasich - Neurologische Klinik, Ludwig-Maximilians-Universität München, 
Munich, Germany; elisabeth.wlasich@med.uni-muenchen.de 
•     Henrik Zetterberg - Dementia Research Institute, Department of Neurodegenerative 
Disease, UCL Institute of Neurology, Queen Square, London, UK; h.zetterberg@ucl.ac.uk 
•     Miren Zulaica - Neuroscience Area, Biodonostia Health Research Insitute, San Sebastian, 
Gipuzkoa, Spain; miren.zulaicaijurco@osakidetza.eus
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPTHighlights 
• mechanisms of preserved function in presymptomatic dementia are not well understood 
• we studied people with genetic frontotemporal dementia and their relatives 
• brain network efficiency was preserved prior to the onset of symptoms 
• highly connected hub regions were preferentially affected by neuropathology 
• interventions to support functional brain networks may delay the onset of dementia 
